Downregulation of topoisomerase IIβ in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest

Leukemia

Volumn 20, Issue 10, 2006, Pages 1809-1818

  Chikamori, K ^a   Hill, J E ^a   Grabowski, D R ^a   Zarkhin, E ^a   Grozav, A G ^a   Vaziri, S A J ^a   Wang, J ^b   Gudkov, A V ^c   Rybicki, L R ^a   Bukowski, R M ^a   Yen, A ^b   Tanimoto, M ^d   Ganapathi, M K ^a   Ganapathi, R ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ISOENZYME; MESSENGER RNA; PEROXIREDOXIN; PEROXIREDOXIN 2; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; UNCLASSIFIED DRUG; 2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II BETA; ENZYME INHIBITOR; HEAT SHOCK PROTEIN; PEROXIDASE; PIPERAZINE DERIVATIVE; PRDX2 PROTEIN, HUMAN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR DIFFERENTIATION; CELL DIVISION; CELL STRAIN HL 60; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOWN-REGULATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; HEAT-SHOCK PROTEINS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; PEROXIDASES; PIPERAZINES; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRETINOIN;

EID: 33750042893     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404351     Document Type: Article

References (30)

1. Kellner U, Sehested M, Jensen PB, Giesler F, Rudolph P. Culprit and victim - DNA topoisomerase II. Lancet Oncol 2002; 3: 235-243.
2. Li T-K, Liu LF. Tumor cell death induced by topoisomerasetargeting drugs. Annu Rev Pharmacol 2001; 41: 53-57.
3. Wang JC. Cellular roles of DNA topoisomerases: A molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-440.
4. Turley H, Comley M, Houlbrook S, Nozaki N, Kikuchi A, Hickson ID et al. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 1997; 75: 1340-1346.
5. Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues durine murine development. Biochim Biophys Acta 1992; 1132: 43-48.
6. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991; 2: 209-214.
7. Yang X, Li W, Prescott ED, Burden SJ, Wang JC. DNA topoisomerase IIβ in neuronal development. Science 2000; 287: 131-134.
8. Tsutsui K, Tsutsui K, Sano K, Kikuchi A, Tokunaga A. Involvement of DNA topoisomerase IIβ in neuronal differentiation. J Biol Chem 2001; 276: 5769-5778.
9. Lyu YL, Wang JC. Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIβ. Proc Natl Acad Sci USA 2003; 100: 7123-7128.
10. Kaufmann SH, McLaughlin SJ, Kastan MB, Liu LF, Karp JE, Burke PJ. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 1991; 51: 3534-3543.
11. Kaufmann SH, Charron M, Burke PJ, Karp JE. Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo. Cancer Res 1995; 55: 1255-1260.
12. Aoyama M, Grabowski DR, Isaacs RJ, Krivacic KA, Rybicki LA, Bukowski RM et al. Altered expression and activity of topoisomerases during all trans retinoic acid induced differentiation of HL-60 cells. Blood 1998; 92: 2863-2870.
13. Chresta CM, Hall BF, Francis GF. Retinoic acid and phorbol ester induced hyperphosphorylation of topoisomerase II is an early event in HL-60 human leukemia cell differentiation: Effect on topoisomerase activity and etoposide sensitivity. Leukemia 1995; 9: 1373-1381.
14. Kim HJ, Lotan R. Identification of retinoid-modulated proteins in squamous carcinoma cells using high-throughput immunoblotting. Cancer Res 2004; 64: 2439-2448.
15. Noy N. Retinoid-binding proteins: Mediators of retinoid action. Biochem J 2000; 348: 195-481.
16. Melnick A, Licht JD. Deconstructing a disease: RAR α, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999; 93: 3167-3215.
17. Collins SJ. The role of retinoid and retinoic acid receptors in normal hematopoiesis. Leukemia 2002; 16: 1896-1905.
18. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004; 328: 1-16.
19. Kastner P, Chan S. Function of RARα during the maturation of neutrophils. Oncogene 2001; 20: 7178-7185.
20. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-193.
21. Zhang P, Liu B, Kang SW, Seo MS, Rhee SG, Obeid LM. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of bcl-2. J Biol Chem 1997; 272: 30615-30639.
22. Herzog CE, Holmes KA, Tuschong LM, Ganapathi R, Zwelling LA. Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIα. Cancer Res 1998; 58: 5298-5300.
23. Sun Y, Kim SH, Zhou D-C, Ding W, Paietta E, Guidez F et al. Acute promyelocytic leukemia cell line AP-1060 establishes as a cytokine-dependent culture from a patient clinically resistant to all-trans-retinoic acid and arsenic trioxide. Leukemia 2004; 18: 1258-1269.
24. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
25. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004; 64: 1951-1958.
26. 0 arrest of HL-60 cells. Eur J Cell Biol 2006; 85: 117-132.
27. Tabata M, Tabata R, Grabowski DR, Bukowski RM, Ganapathi MK, Ganapathi R. Roles of NF-κB and 26S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human non-small cell lung carcinoma. J Biol Chem 2001; 276: 8029-8036.
28. Grabowski DR, Holmes KA, Aoyama M, Ye Y, Rybicki LA, Bukowski RM et al. Altered drug interaction and regulation of topoisomerase IIβ: Potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide. Mol Pharmacol 1999; 56: 1340-1345.
29. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-395.
30. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER et al. Reversible oxidation inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci USA 2004; 101: 16419-16424.